Click here for an updated version of this article.
NEW YORK, Aug. 9 (GenomeWeb News) - Harvard Bioscience, which recently announced that it would divest its capital equipment business, today reported second quarter revenue of $21.7 million, a 3.3 percent drop from revenue of $22.5 million in last year's second quarter.